Emerging anti-HIV drugs (Q36150601)

12 August 2017

1 reference

title

Emerging anti-HIV drugs (English)

1 reference

12 August 2017

Erik De Clercq

0 references

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

241-273

1 reference

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Antivirals and antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

The bicyclam AMD3100 story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

New class of HIV integrase inhibitors that block viral replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

10.1517/14728214.10.2.241

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference